21:48 , Dec 2, 2016 |  BC Week In Review  |  Company News

Chiesi, Atopix deal

Chiesi will acquire Atopix in a deal that could exceed €75 million ($80 million), including undisclosed milestones. Atopix’s OC459 , a prostaglandin D2 (PGD2) receptor subtype DP2 ( PTGDR2 ; CRTH2 ; GPR44 ; DP2;...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Timapiprant: Completed Phase III enrollment

Eleventa and Oxagen announced the completion of enrollment of 212 patients in a double-blind, placebo-controlled, Russian Phase III trial evaluating 50 mg oral timapiprant once daily for 12 weeks. Atopix has exclusive rights from Oxagen...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

OC459: Phase IIb data

A double-blind, international Phase IIb trial in 482 patients with mild to moderate persistent asthma showed that 25 mg once-daily oral OC459 met the primary endpoint of significantly increasing mean FEV1 from baseline to week...
01:58 , Mar 4, 2014 |  BC Extra  |  Clinical News

Atopix reports mixed Phase II asthma data

One dose of OC459 from Atopix Therapeutics Ltd. (London, U.K.) met the primary endpoint while two other doses missed in a Phase IIb trial to treat mild to moderate persistent asthma. In the trial, 25...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

OC459: Phase II started

Atopix began a double-blind, placebo-controlled, European Phase II trial to evaluate once-daily oral OC459 for 6 months. The trial is funded by an £1.7 million ($2.8 million) grant from the U.K. Biomedical Catalyst fund (see...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Atopix Therapeutics, Medical Research Council, U.K. Technology Strategy Board (TSB) dermatology news

In April, Atopix received a £1.7 million ($2.6 million) award from the U.K. Biomedical Catalyst fund to develop the company's lead compound, OC459 , to treat moderate-to-severe atopic dermatitis. The product has completed Phase I...
01:00 , Oct 5, 2012 |  BC Extra  |  Financial News

Russian newco Eleventa debuts with Maxwell investment

Maxwell Biotech Venture Fund said it made an undisclosed investment in Russian newco Eleventa. Eleventa is partnered with Oxagen Ltd. (Abingdon, U.K.) to develop asthma therapy OC459, a prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2)...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Clinical News

OC000459: Completed Phase IIb enrollment

Oxagen completed enrollment of 440 patients in a double-blind, placebo-controlled, European Phase IIb trial evaluating oral OC000459 given once daily for 12 weeks. Oxagen Ltd. , Abingdon, U.K.   Product: OC000459   Business: Inflammation  ...
23:54 , Nov 24, 2009 |  BC Extra  |  Financial News

Oxagen raises L16 million

Oxagen Ltd . (Abingdon, U.K.) raised L16 million ($26.5 million) in a series C round led by Novartis Venture Funds. Existing investors MPM Capital; SV Life Sciences; Advent Ventures; Bessemer Venture Partners; Omega; Abingworth; IBT;...